- Indivior maintained its full-year guidance Wednesday but warned profits could suffer if Dr. Reddy's Laboratories launches a generic version of the company’s sublingual film product.

Indivior maintained its full-year guidance for revenues in the range of $990-$1,020m and net income of $230-255m, but conceded that a rival's generic buprenorphine/naloxone sublingual film entry in 2018, would pose a risk to guidance.

The company didn't quantify the risk, but cited Industry analogs claiming that a launch in the US of a generic product would see its Suboxone sublingual film brand 'losing up to 80% of its market share within a matter of months.'

'Should generic buprenorphine/naloxone sublingual film enter the market in 2018, the result would most likely be a rapid and material loss of market share for Suboxone Sublingual Film' Indivior said.

The unchanged guidance comes a day after the company said a U.S. court had lifted ban, which prevented rival drug maker Dr. Reddy's Laboratories from selling a generic of the company's buprenorphine/naloxone sublingual film product in the U.S.

'While we ultimately believe in the strength of our patent portfolio, we acknowledge that the Company faces challenges in the intervening period resulting from a potential material and rapid loss of market share to generic buprenorphine/naloxone sublingual film competition, including reduced earnings and cash flow,' said Shaun Thaxter, CEO of Indivior.

At 8:42am: [LON:INDV] Indivior Plc share price was -10.67p at 99.28p

Story provided by